Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2614

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2614
---
isable, December 31, 2024   4,437   $116.07   $-    8.73  

The following table summarizes the Company’s
stock option activities during the year ended December 31, 2023:

     Number of Options   Weighted Average Exercise Price   Aggregate Intrinsic Value   Weighted Average Remaining Contractual Life  (Years)   Options outstanding, December 31, 2022   -   $-   $           -    -   Granted   632    318.00    -    5.00   Exercised   -    -    -    -   Forfeited   -    -    -    -   Expired   -    -    -    -   Options outstanding, December 31, 2023   632   $318.00   $-    4.53                          Options vested and exercisable, December 31, 2023   632   $318.00   $-    4.53  

The aggregate intrinsic value in the tables above
reflects the difference between the Company’s closing stock price on the last trading day of the period and the exercise price
of the options, multiplied by the number of in-the-money stock options. The intrinsic value of stock options changes based on the price
of the Company’s common stock.

On July 16, 2024, the effective date of shareholder
approval to increase the number of shares available under the 2022 Plan, the Company determined that the grant date criteria (as defined
in ASC 718) was met, and therefore granted 12,838 stock options to certain directors, executives, and non-employees, in accordance with
the terms of the individuals’ employment or directors’ agreements, as applicable. On September 26, 2024, the Board of Directors
approved the grant of an additional 4,167 stock options to an executive.

For the year ended December 31, 2024, the Company
recognized $32,767 of compensation expense related to stock option awards ($119,246 for the year ended December 31, 2023). No stock options
were exercised, forfeited, or